Universidad Peruana Cayetano Heredia

COVID-19 Therapeutics for Low- and Middle-Income Countries: A Review of Candidate Agents with Potential for Near-Term Use and Impact.

Mostrar el registro sencillo del ítem

dc.contributor.author Maxwell, Daniel
dc.contributor.author Sanders, Kelly C
dc.contributor.author Sabot, Oliver
dc.contributor.author Hachem, Ahmad
dc.contributor.author Llanos Cuentas, Elmer Alejandro
dc.contributor.author Olotu, Ally
dc.contributor.author Gosling, Roly
dc.contributor.author Cutrell, James B
dc.contributor.author Hsiang, Michelle S
dc.date.accessioned 2021-10-04T23:00:56Z
dc.date.available 2021-10-04T23:00:56Z
dc.date.issued 2021
dc.identifier.uri https://hdl.handle.net/20.500.12866/9807
dc.description.abstract Low- and middle-income countries (LMICs) face significant challenges in the control of COVID-19, given limited resources, especially for inpatient care. In a parallel effort to that for vaccines, the identification of therapeutics that have near-term potential to be available and easily administered is critical. Using the United States, European Union, and WHO clinical trial registries, we reviewed COVID-19 therapeutic agents currently under investigation. The search was limited to oral or potentially oral agents, with at least a putative anti-SARS-CoV-2 virus mechanism and with at least five registered trials. The search yielded 1,001, 203, and 1,128 trials, in the United States, European Union, and WHO trial registers, respectively. These trials covered 13 oral or potentially oral repurposed agents that are currently used as antimicrobials and immunomodulatory therapeutics with established safety profiles. The available evidence regarding proposed mechanism of actions, potential limitations, and trial status is summarized. The results of the search demonstrate few published studies of high quality, a low proportion of trials completed, and the vast majority with negative results. These findings reflect limited investment in COVID-19 therapeutics development compared with vaccines. We also identified the need for better coordination of trials of accessible agents and their combinations in LMICs. To prevent COVID-19 from becoming a neglected tropical disease, there is critical need for rapid and coordinated effort in the evaluation and deployment of those agents found to be efficacious en_US
dc.language.iso eng
dc.publisher American Journal of Tropical Medicine and Hygiene
dc.relation.ispartofseries American Journal of Tropical Medicine and Hygiene (ASTMH Journal)
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject COVID-19 en_US
dc.subject Therapeutics en_US
dc.subject Low income countries en_US
dc.subject Middle-Income Countries en_US
dc.subject Review en_US
dc.title COVID-19 Therapeutics for Low- and Middle-Income Countries: A Review of Candidate Agents with Potential for Near-Term Use and Impact. en_US
dc.type info:eu-repo/semantics/review
dc.identifier.doi https://doi.org/10.4269/ajtmh.21-0200
dc.relation.issn 1476-1645


Ficheros en el ítem

Ficheros Tamaño Formato Ver

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

info:eu-repo/semantics/restrictedAccess Excepto si se señala otra cosa, la licencia del ítem se describe como info:eu-repo/semantics/restrictedAccess

Buscar en el Repositorio


Listar

Panel de Control

Estadísticas